ARTICLE | Product Development

Alzheimer’s data from Lilly and Biogen converge on small effect for amyloid targeting

Both corroborate the amyloid hypothesis while simultaneously suggesting it’s not the path to a large effect size

March 15, 2021 12:45 AM UTC

Emerging data from anti-amyloid therapies from Eli Lilly and Biogen continue to mirror each other. Whether the consistent findings will bolster both therapies’ cases with regulators, or whether ...

Access this Article

BCIQ Company Profiles

Biogen Inc.

Eli Lilly and Co.